Skip to main content
Category

Biopharmacy

admin
In Active, Biopharmacy, Regional

Inteliphages

Development of a powerful therapy to fight antimicrobial resistance. The aim of the Inteliphages project is to develop dried and encapsulated phages in order to treat bacterial infections that are either resistant to antibiotics or for which antibiotics are not indicated for other reasons. The development of dried and encapsulated...
Read More
admin
In Active, Biopharmacy, Medical Devices and In Vitro Diagnostics, Regional

AERONEXT

Asthma and COPD (Chronic Obstructive Pulmonary Disease) are amongst the most common causes of mortality and morbidity worldwide, representing together the third largest medical market. Their prevalence is increasing due to the global industrial pollution. Inhaled therapies, the preferred treatment options, are made of a drug combined with a medical...
Read More
admin
In Active, Biopharmacy, Radiation applied to health, Regional

FAR

When surgical removal is not possible, oncologists have few treatment options to offer their cancer patients. Trasis, Xpress Biologics, CMMI (ULB) and UMONS are embarking on the FAR (Fragments of Antibodies for Radioimmunotherapy) research project to promote the use of antibody fragments as carriers of radioactive isotopes. By using both the ability of antibody fragments to target tumours and...
Read More
admin
In Active, Biopharmacy, Medical Devices and In Vitro Diagnostics, Regional

BoneRec

The BoneRec project aims to develop a new tissue-engineered product indicated for bone reconstruction. This ideal bone graft substitute will be biomechanically stable, resorbable and will have osteoconductive, osteogenic and osteoinductive properties. The biomechanical property will be provided by Cerhum's ceramic graft (coordinating company of the project) and the osteoconductive,...
Read More
admin
In Active, Biopharmacy, Radiation applied to health, Regional

M2-TARGET

M2-Target aims to develop a non-invasive imaging method for the detection and quantification of M2 macrophages. This method is based on a new radiotracer (called 68Ga-ABSCINT-206) initially developed at the Vrije Universiteit Brussel (VUB). It is composed of a single-domain antibody fragment (also called "nanobodies") that recognizes a receptor (CD206)...
Read More